← Back to Clinical Trials
Recruiting NCT07531732

NCT07531732 Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07531732
Status Recruiting
Phase
Sponsor Assistance Publique - Hôpitaux de Paris
Condition Frontotemporal Dementia, Behavioral Variant
Study Type OBSERVATIONAL
Enrollment 34 participants
Start Date 2026-04
Primary Completion 2027-12

Trial Parameters

Condition Frontotemporal Dementia, Behavioral Variant
Sponsor Assistance Publique - Hôpitaux de Paris
Study Type OBSERVATIONAL
Phase N/A
Enrollment 34
Sex ALL
Min Age 50 Years
Max Age 80 Years
Start Date 2026-04
Completion 2027-12
Interventions
Computer-based facial expression recognition taskComputerized affective taskUCLA Structured Insight Interview

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This monocentric, non-interventional study (SELFSOC) investigates the relationship between self-awareness and social cognition in patients with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD). The primary objective is to assess metacognitive efficiency related to social cognitive performance using a computerized facial emotion recognition task combined with confidence judgments. Metacognitive indices (including Mratio) will quantify the correspondence between subjective and objective performance. Thirty-four participants (17 bvFTD, 17 AD; age 50-80; MMSE ≥20) will complete two study visits involving tasks assessing emotion recognition, theory of mind, and memory.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of possible or probable behavioral variant frontotemporal dementia according to the Rascovsky 2011 criteria (DLFTvc group) OR * Diagnosis of Alzheimer's disease according to the Jack 2018 criteria, including biomarkers (MA group) * Mini-Mental State Examination (MMSE) ≥ 20 * Age: 50-80 years * Sufficient reading and writing proficiency in French to enable completion of the study procedures, in the investigator's opinion Exclusion Criteria: * Moderate to severe language disorders: Confrontation naming (DO 40 scale) ≤ 32 * Inability to perform computerized tasks according to the investigator's opinion * Other neurological disorders (including epilepsy, Lewy body disease, vascular dementia) * Psychiatric comorbidities (bipolar disorder, schizophrenia, current major depressive episode) * Uncorrected visual impairment

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology